Home > Professor (CV) > Bibliography (Reviews)

Professor

Bibliography (Reviews)

  1. Morishita R, Gibbons GH, Dzau VJ. Analysis of cellular uptake of antisense oligonucleotides using FITC labeled oligonucleotides. Oligotechniques 1994;2:1-3.
  2. Dzau VJ, Gibbons GH, Morishita R, Pratt E. New perspectives in hypertension research: potentials of vascular biology. Hypertension 1994;23:1132-1140.
  3. Dzau VJ, Morishita R, Gibbons GH. Cardiovascular gene therapy: possibilities and realities. Proceedings of the 3rd International Symposium On Multiple Risk Factors In Cardiovascular Disease Vascular And Organ Protection (in press)
  4. Morishita R, Gibbons GH, Dzau VJ. Potential for transcatheter application of antisense oligonucleotides for treatment of vascular diseases. Journal of Interventinal Cardiology 1995;8:377-381.
  5. Kaneda Y, and Morishita R. In vivo gene transfer for the therapy of vascular diseases. Journal of Atherosclerosis Society. 1995;22:819-823.
  6. Kaneda Y, Morishita R, Tomita N. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Journal of Molecular Medicine 1995:73:289-297.
  7. Morishita R, Higaki J, Aoki M, Hayashi S, Kida I, Kaneda Y, Ogihara T. Novel strategy of gene therapy in cardiovascular disease with HVJ-liposome method. In “Progression of chronic renal diseases”, Koide H (eds.) Contribution to Nephrology, 1996;118:254-264.
  8. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996;93:11421-11425.
  9. Morishita R, Aoki M, Nakamura S, Matsushita H, Tomita N, Hayashi S, Moriguchi A, Matsumoto K, Nakamura T, Ogihara T. Potential role of a novel vascular modulator, hepatocyte growth factor (HGF), in cardiovascular disease; characterization and regulation of local HGF system. Journal of Atherosclerosis and Thrombosis 1997;4:12-19.
  10. Tomita N, Morishita R, Higaki J, Ogihara T. Strategy for functional inactivation of genes:a novel strategy for gene therapy and gene regulation analysis using transcriptional factor decoy oligonucleotides. Experimental Nephrology 1997;5:429-434.
  11. Kaneda Y, Morishita R, Dzau VJ. Prevention of restenosis by gene therapy. Ann NY Acad Sci 1997;811:299-308
  12. Mann MJ, Morishita R, Gibbons GH, von-der-Leyen HE, Dzau VJ. DNA transfer into vascular smooth muscle using fusigenic Sendai virus (HVJ)-liposomes. Molecular Cellular Biochemstry 1997;172:3-12.
  13. Morishita R, Ogihara T. In vivo evaluation of in vitro hypothesis using “gain or loss” of function: functional analysis of renin-angiotensin system. American Journal of Hypertension 1998;11:507-513.
  14. Morishita R, Nakamura S, Hayashi S, Aoki M, Matsushita H, Tomita N, Yamamoto K, Moriguchi A, Higaki J, Ogihara T. Contribution of a vascular modulator, hepatocyte growth factor (HGF), to the pathogenesis of cardiovascular disease. Journal of Atherosclerosis and Thrombosis 1998;4:129-134.
  15. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor “decoy” strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circulation Research 1998;82:1023-1028
  16. Morishita R. Lessons from human arteries: how to design a gene therapy strategy for treatment of cardiovascular disease. (Editorial) Circulation Research 1998;82:1349-1351
  17. Morishita R, Nakagami H, Taniyama Y, Matsushita H, Yamamoto K, Tomita N, Moriguchi A, Matsumoto K, Higaki J, Ogihara T. Oligonucleotide-based gene therapy for cardiovascular disease. Clinical Chemistry and Laboratory Medicine 1998;36:529-534
  18. Dzau VJ, von-der-Leyen HE, Morishita R. The concept and potentials of cardiovascular gene therapy. Indian Heart J. 1998;50:23-33
  19. Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ-liposomes: the best of both worlds ? Molecular Medicine Today 1999;7:298-303.
  20. Morishita R, Moriguchi A, Higaki J, Ogihara T. Hepatocyte growth factor as potential index of severity of hypertension. Hypertension Research 1999;22:161-167
  21. Morishita R, Aoki M, Ogihara T. Functional analysis of cardiovascular renin-angiotensin system using “gain or loss” of function approach. Hypertension Research 2000;23:137-141
  22. Morishita R, Aoki M, Kaneda Y. Oligonucleotides-based gene therapy for cardiovascular disease: are oligonucleotides therapeutics novel cardiovascular drugs ? Current Drug Targets 2000;1:15-23.
  23. Tomita N, Morishita R, Kaneda Y, Higaki J, Ogihara T. Gene therapy as a potential treatment for restenosis and myocardial infarction. Drug News & Perspectives 2000;13:206-212.
  24. Aoki M, Morishita R, Taniyama Y, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by hepatocyte growth factor: potential gene therapy for ischemic diseases. J Atheroscler Thromb. 2000;7:71-76.
  25. Tomita N, Morishita R, Higaki J, Ogihara T. Novel molecular therapeutic approach to cardiovascular disease based on hepatocyte growth factor. J Atheroscler Thromb. 2000;7:1-7.
  26. Morishita R, Aoki M, Kaneda Y, Ogihara T. Gene Therapy in vascular medicine: recent ad vances and future perspectives. Pharmacology & Therapeutics 2001;91:105-114
  27. Nakamura H, Morishita R, Kaneda Y. Molecular therapy via transcriptional regulation with double-stranded oligodeoxynucleotides as decoys. In Vivo 2002;16:45-48
  28. Tomita N, Morishita R, Tomita T, Ogihara T. Potential therapeutic applications of decoy oligonucleotides. Current Opinion in Molecular Therapeutics 2002;4:166-170
  29. Morishita R, Kaneda Y. HVJ (hemagglutinating virus of Japan; Sendai virus)-liposome method.Methods Enzymol. 2002;346:619-27.
  30. Morishita R, Aoki M, Yo Y, Ogihara T. Hepatocyte growth factor as “cardiovascular hormone”: role of HGF in the pathogenesis of cardiovascular disease. Endocrine Journal 2002;49:273-284
  31. Morishita R, Aoki M, Hashiya N, Yamasaki K, Makino H, Wakayama K, Azuma J, Ogihara T. Hepatocyte growth factor (HGF) angiogenic gene therapy: promises for cardiovascular diseases Gene Therapy & Regulation 2002;1:343-359
  32. Morishita R, Tomita N, Ogihara T. HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque. Current Drug Targets 2002;3:379-385
  33. Morishita R, Ogihara T. Gene therapy for peripheral arterial occlusive disease. Japan Medical Association Journal 2002;45:496-498
  34. Morishita R. Recent progress in gene therapy to treat cardiovascular disease. Circulation Journal 2002;66:1077-1086
  35. Tomita N, Morishita R, Tomita T, Azuma H, Ogihara T. NF-kB as a target for transcription factor decoy strategy in inflammatory diseases. Current Medicinal Chemistry 2003;2:51-56
  36. Tomita N, Azuma H, Kaneda Y, Ogihara T, Morishita R. Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases. Current Drug Targets 2003;4:339-346
  37. Morishita R. Cardiovascular disease and angiogenesis. Internal Medicine. 2003;42:301-302
  38. Tomita N, Tomita T, Yuyama K, Tougan T, T Tajima, Ogihara T, Morishita R. Development of novel decoy oligonucleotides: adavantages of circular dumb-bell decoy. Current Opinion in Molecular Therapeutics. 2003;5:107-112
  39. Morishita R, Aoki M, Kaneda Y, Ogihara T. Therapeutic potential of oligonucleotides-based therapy in cardiovascular disease. BioDrugs 2003;17:383-389.
  40. Morishita R. Transcription factor as molecular targets: is transcription factor decoy a novel drug ? Current Drug Target 2003;4:2 p before 599
  41. Tomita N, Morishita R, Ogihara T. Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design. Current Drug Target 2003;4:603-608
  42. Aoki M, Morishita R, Ogihara T. Oligonucleotide-based molecular therapy for restenosis sfter angioplasty. Current Drug Target 2003;4:613-618.
  43. Morishita R, Tomita N, Kaneda Y, Ogihara T. Molecular therapy to inhibit NFkB activation by transcription factor decoy oligonucleotides. Current Opinion in Pharmacology 2004;4:139-146
  44. Kotani H, Nakajima T, Morishita R, Kaneda Y. Innovative novel vectors for cardiovascular disease. Current Gene Therapy 2004;4:183-194
  45. Morishita R, Aoki M, Hashiya N, Yamasaki K, Kurinami H, Shimizu S, Makino H, Takeya Y, Azuma J, Ogihara T. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Current Gene Therapy 2004;4:199-206
  46. Morishita R. Perspective in progress of cardiovascular gene therapy. Journal of Pharmacological Science 2004;95:1-8
  47. Morishita R. Is VEGF a missing link between hypertension and inflammation ? Hypertension (Editorial) 2004;44:253-254
  48. Tomita N, Azuma H, Kaneda Y, Ogihara T, Morishita R. Application of decoy oligodeoxynucleotides-based approach to renal diseases. Curr Drug Targets. 2004;5:717-733.
  49. Tomita N, Morishita R. Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases Current Pharmaceutical Design. 2004;10:797-803.
  50. Nakagami H, Kaneda Y, Ogihara T Morishita R.. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Current Diabetes Review 2005;1:59-63
  51. Nakagami H, Kaneda Y, Ogihara T, Morishita R. Hepatocyte growth factor as potential cardiovascular therapy. Expert Review of Cardiovascular Therapy 2005;3:513-519
  52. Morishita R, Aoki M, Ogihara T. Does gene therapy become pharmacotherapy? Experimental Physiology 2005;3:307-313
  53. Sato N, Shimamura M, Morishita R. Recent progress in cerebrovascular gene therapy. Current Neurovascular Research 2005;2:235-247
  54. Morishita R. Scientific rationale of the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atherosclerosis 2005;6:41-46.
  55. Shimamura M, Sato N, Yoshimura S, Kaneda Y, Morishita R. HVJ-based non-viral gene transfer method: successful gene therapy using HGF and VEGF genes in experimental ischemia. Frontiers in Bioscience 2006;11:753-759
  56. Nakagami H, Tomita N, Kaneda Y, Ogihara T, Morishita R.. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis: anti-oxidant gene therapy by NFkB decoy oligonucleotide. Current Pharmaceutical Biotechnology 2006;7:95-100.
  57. Nakagami H, Morishita R, Maeda K, Kikuchi Y, Ogihara T, Kaneda Y.Adipose tissue-derived stromal cells as a novel option for regenerative cell therapy. Journal of Atherosclerosis and Thrombosis. 2006;13:77-81.
  58. Kawakami K, Nakajima O, Morishita R, Nagai R. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties. The Scientific World Journal 2006;6:781-90.
  59. Tomita N, Kashihara N, Morishita R. Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease. Clin Exp Nephrol. 2007;11:7-17.
  60. Nakagami H, Morishita R. Recent progress in therapeutic angiogenesis. International Journal of Biomedical Science. 2007;3:153-158.
  61. Takeda S, Sato N, Ogihara T, Morishita R. The renin-angiotensin system, hypertension and cognitive dysfunction in alzheimer’s disease: new therapeutic potential. Frontiers in Bioscience 2008;13:2253-2265
  62. Morishita R. Aegis against stroke and dementia by AT1 receptor blockers (ARBs): new beneficial aspects (Editorial). Hypertension Research 2008;31:1-3
  63. Morishita R. Statin biology beyond cholesterol lowering: hepatic statins vs. vascular statins (Editorial). Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry. 2008;2:103-104
  64. Nakagami H, Morishita R. Pleiotrophic effect of statins as antioxidants on cardiac hypertrophy. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry. 2008;2:167-171
  65. Nakagami H, Morishita R. Aging of blood vessels. Anti-Aging Medicine 2008;5:73-77
  66. Miyake T, Morishita R. Pharmacological treatment of abdominal aortic aneurysm. Cardiovascular Research 2009;83:436-443
  67. Katsuya T, Morishita R, Rakugi H, Ogihara T. Genetic basis of hypertension for the development of tailored medicine. Hypertension Research 2009;32:643-648
  68. Suzuki J, Isobe M, Morishita R, Nagai R. Nucleic acid drugs for prevention of cardiac rejection. Journal of Biomedical Biotechnology 2009;2009:916514
  69. Suzuki J, Isobe M, Morishita R, Nagai R. Tea polyphenols regulate key mediators on inflammatory cardiovascular diseases. Mediators Inflammation. 2009;2009:494928
  70. Suzuki J, Isobe M, Morishita R, Nagai R. Characteristics of chronic rejection in heart transplantation –Important elements of pathogenesis and future treatments-. Circulation Journal 2010;74:233-239
  71. Taniyama Y, Morishita R. Does therapeutic angiogenesis overcome CKD? Hypertens Research. 2010;33:114-115.
  72. Katsuya T, Morishita R. The challenge of stopping the knocking down of metabolic dominos upstream. Hypertens Res. 2010;33:529-530
  73. Takeda S, Sato N, Rakugi H, Morishita R. Plasma beta-amyloid as potential biomarker of alzheimer disease: possibility of diagnostic tool of alzheimer disease. Molecular BioSystems 2010;6,1760-1766
  74. Morishita R. Shadows of a rising sun. Nature 2010;467:2P(b158-159)
  75. Morishita R, Komuro I, Horiuchi M, Minamino T, Higashi Y. Anti-aging medicine in cardiovascular disease. Anti-Aging Medicine 2010;7:45-49
  76. Morishita R, Kanda Y, Nakajima M. Irbesartan: second generation of ARB as metabosartan. Current Hypertension Reviews 2010;6:173-179
  77. Morishita R. How to establish real world medicine in Japanese population: Important lessons from JIKEI, CASE-J, KYOTO, and VART Study. Hypertension Research 2011;34:33-35
  78. Nakagami H, Osako MK, Morishita R. New concept of vascular calcification and metabolism. Current Vascular Pharmacology. 2011;9:124-127
  79. Nakagami H, Morishita R. Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ. Current Vascular Pharmacology. 2011;9:162-166.
  80. Morishita R. Winds of Innovation from the East. Nature Medicine 2011:17:516-517after 514.
  81. Sato N, Takeda S, Uchino-Yamada K, Ueda H, Fujisawa T, Rakugi H, Morishita R. Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential. Current Aging Science 2011, 4, 000-000
  82. Takeda S, Sato N, Rakugi H, Morishita R. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: Beta-amyloid peptide, insulin signaling, and neuronal function. Molecular BioSystems 2011;7:1822-1827.
  83. Suzuki J, Ogawa M, Watanabe R, Morishita R, Hirata Y, Nagai R, Isobe M. Autoimmune giant cell myocarditis -- clinical characteristics, experimental models and future treatments. Expert Opinion of Therapeutic Targets 2011;15:1-10
  84. Nakagami H, Osako MK, Morishita R. New concept of vascular calcification and metabolism. Current Vascular Pharmacology. 2011;9:124-127
  85. Nakagami H, Morishita R. (Editorial) Can Forkhead Box P1 be a novel therapeutic target for atherosclerosis? Atherosclerosis 2011;218:26-27.
  86. Shimamura M, Sato N, Morishita R. Experimental and clinical application of plasmid DNA in the field of central nervous diseases. Current Gene Therapy. 2011 11:491-500
  87. Morishita R. (Editorial) A new bench mark in the hypertension world. World Journal of Hypertension. 2011;1:1-2
  88. Taniyama Y, Azuma J, Rakugi H, Morishita R. Plasmid DNA-based Gene Transfer with Ultrasound and Microbubbles. Current Gene Therapy. 2011 11:485-490
  89. Shimamura M, Morishita R. Naked plasmid DNA for gene therapy. Current Gene Therapy. 2011;11:491-500.
  90. Morishita R. (Editorial) New Wave from Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry. 2012;12:1
  91. Minhas G, Morishita R, Anand A. Preclinical models to investigate retinal ischemia: Advances and drawbacks. Frontiers in Neuro-Ophthalmology 2012;3:75. doi: 10.3389/fneur.2012.00075
  92. Sato N, Shinohara M, Rakugi H, Morishita R. Dual Effects of Statins on Aβ Metabolism: Upregulation of the Degradation of APP-CTF and Aβ Clearance. Neurodegener Disease. 2012;10:305-308.
  93. Kyutoku M, Nakagami H, Nakagami F, Koriyama H, Osako MK, Shimamura M, Miyake T, Morishita R. Lipoprotein(a) is a therapeutic target for cardiovascular disease. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 2012;12:118-121
  94. Taniyama Y, Azuma J, Iekushi K, Sanada F, Iwabayashi M, Kusunoki H, Okayama K, Otus R, Rakugi H, Morishita R. The HGF/c-Met receptor system under pathological conditions. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 2012;12:122-129
  95. Suzuki J, Morishita R. A New Era of Gene Therapy. Current Topics in Medicinal Chemistry. 2012;12:1593.
  96. Taniyama Y, Azuma J, Iekushi K, Rakugi H, Morishita R. Therapeutic Option of Plasmid-DNA Based Gene Transfer. Current Topics in Medicinal Chemistry, 2012;12:1630-1637
  97. Shimamura M, Sato N, Nakagami H, Taniyama Y, Morishita R. Development of Nucleic Acid Drugs for Neurological Disorders. Current Topics in Medicinal Chemistry. 2012;12:1621-1629.
  98. Miyake T, Nakagami H, Morishita R. Nucleic Acid Drugs for Preventing Restenosis after Coronary Revascularization. Current Topics in Medicinal Chemistry. 2012;12:1613-1620.
  99. Suzuki J, Isobe M, Morishita R, Nagai R. Applications of Nucleic Acid Drugs for Organ Transplantation. Current Topics in Medicinal Chemistry. 2012;12:1608-1612.
  100. Osako MK, Nakagami H, Morishita R. Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy. Current Topics in Medicinal Chemistry 2012;12:1603-1607.
  101. Osako MK, Nakagami H, Morishita R. Development and Modification of Decoy Oligodeoxynucleotides for Clinical Application. Advanced Polymer Science 2012;249:49–60
  102. Morishita R. A warm welcome to the New Year 2013: From Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 2013;13:1
  103. Morishita R, Yamagishi S. A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of Linagliptin. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 2013;13:81-88
  104. Katsuya T, Morishita R. Gene Polymorphism of Angiotensin II Type 1 and Type 2 Receptors. Current Pharmceutical Design. 2013;19:2996-3001.
  105. Kurinami H, Shimamura M, Sato N, Nakagami H, Morishita R. Do Angiotensin Receptor Blockers Protect Against Alzheimer's Disease? Drugs & Aging 2013;30:367-372. doi: 10.1007/s40266-013-0071-2.
  106. Sato N, Morishita R. Plasma Aβ: A Possible Missing Link between Alzheimer Disease and Diabetes Mellitus. Diabetes 2013;62:1005-1006. doi: 10.2337/db12-1549.
  107. Nakagami H, Osako MK, Morishita R. Potential effect of angiotensin II receptor blockade in adipose tissue and bone. Current Pharmceutical Design. 2013;19:3049-3053.
  108. Saito Y, Nakagami H, Kaneda Y, Morishita R. Lymphedema and Therapeutic Lymphangiogenesis. BioMed Research International. 2013. doi:10.1155/2013/804675.
  109. Shimamura M, Nakagami H, Morishita R. Gene Therapy and Cell-Based Therapies for Therapeutic Angiogenesis in Peripheral Artery Disease. BioMed Research International. 2013, http://dx.doi.org/10.1155/2013/186215.
  110. Morishita R, Tomita N, Ogihara T. Statin biology beyond cholesterol lowering: vascular statin vs. hepatic statin. Expert Review of Cardiovascular Therapy (in press)
  111. Morishita R. Gene Therapy in cardiovascular medicine: recent advances and perspectives. Drugs of Today (in press)
  112. Suzuki J, Isobe M, Morishita R, Nagai R. Effects of tea catechins on inflammation-related cardiovascular disease. Currrent Immunology Review (in press)
  113. Sato N, Morishita R. Roles of Vascular and Metabolic Components in Cognitive Dysfunction of Alzheimer disease: Short- and Long-term Modification by Non-genetic Risk Factors. Frontiers in Aging Neuroscience (in press)
[Professor: Ryuichi Morishita]
Page Top